Welcome to our dedicated page for Revolution SEC filings (Ticker: RVMDW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Revolution's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Revolution's regulatory disclosures and financial reporting.
Revolution Medicines announced that Steve Kelsey, M.D., will retire from his employment effective January 4, 2027. He will transition from president, research and development to senior advisor to the chief executive officer on July 1, 2026, and the company contemplates appointing him to its board of directors at retirement, subject to board approval.
The company also reported results from its annual meeting of stockholders. Stockholders elected Class III directors Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D., to terms ending at the 2029 annual meeting. They ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of named executive officers.
Revolution Medicines announced that Steve Kelsey, M.D., will retire from his employment effective January 4, 2027. He will transition from president, research and development to senior advisor to the chief executive officer on July 1, 2026, and the company contemplates appointing him to its board of directors at retirement, subject to board approval.
The company also reported results from its annual meeting of stockholders. Stockholders elected Class III directors Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D., to terms ending at the 2029 annual meeting. They ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of named executive officers.
Revolution Medicines executive Anthony Mancini reported an automatic sale of shares to cover taxes on vested stock units. On the transaction date, 4,615 shares of common stock were sold in open-market trades at a weighted average price of $156.1192 per share.
The filing explains that this was an automatic sell-to-cover solely for applicable withholding taxes following restricted stock unit vesting, rather than a discretionary sale. After the transaction, Mancini held 49,975 shares directly, including 43,700 restricted stock units and 190 shares acquired under the company’s Employee Stock Purchase Plan.
Revolution Medicines executive Anthony Mancini reported an automatic sale of shares to cover taxes on vested stock units. On the transaction date, 4,615 shares of common stock were sold in open-market trades at a weighted average price of $156.1192 per share.
The filing explains that this was an automatic sell-to-cover solely for applicable withholding taxes following restricted stock unit vesting, rather than a discretionary sale. After the transaction, Mancini held 49,975 shares directly, including 43,700 restricted stock units and 190 shares acquired under the company’s Employee Stock Purchase Plan.
Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.
Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.
Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.
Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.
Revolution Medicines, Inc. General Counsel Jeff Cislini reported an open-market sale of 2,157 shares of common stock at a weighted average price of $156.1191 per share. The trade was executed under a Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. After this transaction, he holds 56,521 shares, including 43,514 restricted stock units and 160 shares acquired through the company’s Employee Stock Purchase Plan.
Revolution Medicines, Inc. General Counsel Jeff Cislini reported an open-market sale of 2,157 shares of common stock at a weighted average price of $156.1191 per share. The trade was executed under a Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. After this transaction, he holds 56,521 shares, including 43,514 restricted stock units and 160 shares acquired through the company’s Employee Stock Purchase Plan.
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,722 shares of common stock at an average price of $156.1192 per share. The sale was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs, and Jack now holds 123,269 shares, including 51,388 RSUs and 479 shares acquired through the employee stock purchase plan.
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,722 shares of common stock at an average price of $156.1192 per share. The sale was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs, and Jack now holds 123,269 shares, including 51,388 RSUs and 479 shares acquired through the employee stock purchase plan.
Revolution Medicines, Inc. executive Stephen Michael Kelsey reported an open-market sale of 4,175 shares of common stock on June 16, 2026 at a weighted average price of $156.1192 per share. The footnotes state this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter intended to satisfy tax withholding obligations related to vested restricted stock units. After the sale, Kelsey directly owned 291,876 shares, which the disclosure notes includes 76,251 RSUs and 653 shares acquired through the company’s Employee Stock Purchase Plan.
Revolution Medicines, Inc. executive Stephen Michael Kelsey reported an open-market sale of 4,175 shares of common stock on June 16, 2026 at a weighted average price of $156.1192 per share. The footnotes state this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter intended to satisfy tax withholding obligations related to vested restricted stock units. After the sale, Kelsey directly owned 291,876 shares, which the disclosure notes includes 76,251 RSUs and 653 shares acquired through the company’s Employee Stock Purchase Plan.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a mix of option exercises and stock sales. On June 15 and June 17, 2026, she exercised stock options covering a total of 90,000 shares of common stock at exercise prices of $26.50, $29.80, and $40.74 per share.
Across June 15 and June 17, 2026 and June 16, 2025, she sold 93,575 shares of common stock in open-market transactions at weighted average prices around $156–$160 per share. Footnotes state that the 2026 transactions were effected under a Rule 10b5-1 trading plan and that an earlier Rule 10b5-1 instruction letter addressed tax withholding obligations on RSU vesting.
After these transactions, Horn continues to hold a significant direct equity position, including restricted stock units noted in the footnotes.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a mix of option exercises and stock sales. On June 15 and June 17, 2026, she exercised stock options covering a total of 90,000 shares of common stock at exercise prices of $26.50, $29.80, and $40.74 per share.
Across June 15 and June 17, 2026 and June 16, 2025, she sold 93,575 shares of common stock in open-market transactions at weighted average prices around $156–$160 per share. Footnotes state that the 2026 transactions were effected under a Rule 10b5-1 trading plan and that an earlier Rule 10b5-1 instruction letter addressed tax withholding obligations on RSU vesting.
After these transactions, Horn continues to hold a significant direct equity position, including restricted stock units noted in the footnotes.
Revolution Medicines insider Mark A. Goldsmith reported sales of Common Stock via Form 144. The filing lists a transfer of 12,871 shares on 03/17/2026 for $1,280,412.23 and a transfer of 120,000 shares on 04/15/2026 for $18,010,488.00. The filing also shows restricted stock unit grants of 3,488, 3,018 and 3,266 awarded on 03/01/2023, 03/01/2024 and 03/01/2025, respectively.
Revolution Medicines insider Mark A. Goldsmith reported sales of Common Stock via Form 144. The filing lists a transfer of 12,871 shares on 03/17/2026 for $1,280,412.23 and a transfer of 120,000 shares on 04/15/2026 for $18,010,488.00. The filing also shows restricted stock unit grants of 3,488, 3,018 and 3,266 awarded on 03/01/2023, 03/01/2024 and 03/01/2025, respectively.
Revolution Medicines, Inc. sale notice by affiliate Jeff Cislini for Common Stock under Rule 144. The filing lists two reported dispositions: 1,795 shares sold on 03/17/2026 for $178,567.32 and 1,163 shares sold on 03/19/2026 for $113,322.72. The form also lists several restricted stock unit grants with grant dates and share counts as background.
Revolution Medicines, Inc. sale notice by affiliate Jeff Cislini for Common Stock under Rule 144. The filing lists two reported dispositions: 1,795 shares sold on 03/17/2026 for $178,567.32 and 1,163 shares sold on 03/19/2026 for $113,322.72. The form also lists several restricted stock unit grants with grant dates and share counts as background.
Revolution Medicines reported the sale of 2,753 shares of Common Stock by a selling party on 03/17/2026, with proceeds shown as $273,869.54.
The filing also lists prior restricted stock unit grants of 318, 846, 840, and 649 shares dated 09/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025, respectively.
Revolution Medicines reported the sale of 2,753 shares of Common Stock by a selling party on 03/17/2026, with proceeds shown as $273,869.54.
The filing also lists prior restricted stock unit grants of 318, 846, 840, and 649 shares dated 09/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025, respectively.